Participated · Seed · Mar 2026

Surf Therapeutics is developing a patented, non-invasive ultrasound neuromodulation platform aimed at treating chronic inflammatory disorders, specifically rheumatoid arthritis. The company is clinical-stage and led by CEO Nishant Doctor. It seeks to safely bring this non-invasive therapy into the home to provide scalable relief without drugs or surgery. The firm is based in Austin, TX. The company reported it will use newly received investment capital to expand its development efforts. No revenue, user metrics, past funding rounds, or valuation figures were disclosed in the article.

Led · Seed · Nov 2025

Planet Smart’s flagship product is PlanetSorb, a naturally biodegradable, high-performance superabsorbent polymer (SAP) derived from poly-amino acids that breaks down in soil or landfill within six months without leaving microplastics. The material absorbs more than one litre of liquid per gram—up to twice the capacity of conventional SAPs—allowing manufacturers to use less material for thinner, more comfortable products at comparable cost. The company has secured three letters of intent with leading hygiene manufacturers and received two purchase orders from European brands, validating early commercial interest. Independent lab testing confirms PlanetSorb is non-toxic, dermatologist-approved, and maintains high absorbency and liquid retention. With fresh capital, Planet Smart will scale beyond its current lab setup, run pilot trials, and target a production capacity of one kilotonne (roughly 45 million nappies) by the end of 2028. The team also plans to raise additional funds in 2026 to expand manufacturing and pursue licensing partnerships with global brands. Longer term, Planet Smart sees use cases for its biodegradable absorbents in agriculture, wound care, food packaging, and mining waste management.

Participated · Seed · Aug 2022

Constructive Bio develops proprietary genome-synthesis and protein-translation platforms that turn living cells into biofactories capable of creating sustainable materials and novel therapeutics. The company writes entire custom genomes with full control of the genetic sequence and engineers protein translation to biomanufacture entirely new molecules with novel properties and functions. It reports having optimised its synthetic organisms and demonstrated scalable production of multi-functionalised proteins at commercial titres. Since launching in 2022, Constructive Bio says it has unlocked commercial potential across pharmaceuticals, chemicals, materials and consumer goods. The company intends to use new funding to further develop its technology to create new therapeutics and synthesise pharmaceuticals at scale. Financially, the company has raised $58M in a Series A and $75M in total to date. Constructive Bio is a Cambridge, UK-based biotechnology company focused on platform technologies that enable genome-scale engineering and synthesis of non-natural polymers. The company is built on two proprietary platforms: large-scale DNA assembly, which can construct large chunks of DNA including whole bacterial genomes, and genome reprogramming to systematically recode whole genomes. Constructive Bio signed an exclusive license from the Medical Research Council to IP developed by Professor Jason Chin’s Laboratory at the MRC Laboratory of Molecular Biology. Chin Lab methods enable organisms that use new genetic codes, yielding properties such as broad viral (phage) resistance and the ability to produce unnatural polymers and novel functions. Constructive Bio plans to use its platforms to synthesise polymers with non-natural amino acids for commercial applications across therapeutics, antibiotics, agriculture, manufacturing and materials. The company also intends to leverage the phage resistance of its engineered organisms to increase bio-manufacturing yields. It raised $15M in seed funding to build out these technology platforms for commercial application.